The FoxO1 inhibitor had a strong effect on CLL cell viability in vitro (see above), and we further tested its effects in coculture models, which provide resistance to cytostatic drugs, venetoclax, or monoclonal antibodies (43–46). This evidence concerns the gene FOXO1 and B-cell chronic lymphocytic leukemia.